Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Affymetrix_SNP6_segmented - samples

ABSTRACT: Segmented copy number data

PROVIDER: EGAD00010000440 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31.

Viré Emmanuelle E Curtis Christina C Davalos Veronica V Git Anna A Robson Samuel S Villanueva Alberto A Vidal August A Barbieri Isaia I Aparicio Samuel S Esteller Manel M Caldas Carlos C Kouzarides Tony T

Molecular cell 20140227 5

Amplification of the EMSY gene in sporadic breast and ovarian cancers is a poor prognostic indicator. Although EMSY has been linked to transcriptional silencing, its mechanism of action is unknown. Here, we report that EMSY acts as an oncogene, causing the transformation of cells in vitro and potentiating tumor formation and metastatic features in vivo. We identify an inverse correlation between EMSY amplification and miR-31 expression, an antimetastatic microRNA, in the METABRIC cohort of human ...[more]

PMID: 24582497

Similar Datasets

Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP-arrays

Project description:We describe a method for automatic detection of absolute segmental copy numbers and genotype status in complex cancer genome profiles measured by SNP arrays. The method is based on pattern recognition of segmented and smoothed copy number and allelic imbalance profiles. Overall copy number assignments were verified by DNA indexes of breast carcinomas and karyotypes of cell lines. The method performs well even for poor quality data, low tumor content, and highly rearranged tumor genomes.

2009-10-30 | GSE18799 | GEO

Affymetrix CytoScan 750K and HD data for developmental delay and/or physical disability phenotypes samples

Project description:Chromosomal copy number variations (CNV) have been associated with various neurological and developmental disorders and chromosomal microarray (CMA) is a method of choice to diagnose Copy Number Gain/Loss syndromes. Recently, next-generation sequencing (NGS)-based low-coverage whole genome sequencing (LC-WGS) has been applied to detect Copy Number Gain/Loss syndromes. This dataset is intended to be used as a “Golden standard data set” for development of LC-WGS analysis method. It consists of patients (n=63) who have a mental delay and/or physical disability phenotype and normal (n=20) phenotype.

2018-09-29 | GSE120624 | GEO

Gene expression profiles of retinoblastoma cell lines

Project description:In order to identify the gene targets of frequently altered chromosomal regions in retinoblastoma, a meta-analysis of genome-wide copy number alterations studies on primary retinoblastoma tissue and retinoblastoma cell lines was performed. Published studies were complemented by copy number and gene expression analysis on primary and cell line samples of retinoblastoma. This dataset includes the gene expression data of the retinoblastoma cell lines This data set contains the gene expression (Affymetrix human genome u133 plus 2.0 PM) results for 7 unique retinoblastoma cell lines. For one of the 7 unique cell lines, 3 RNA isolations were performed and were profiled on seperate arrays, adding up to 9 unique array files. Copy number data for primary retinoblastoma (tumor and blood DNA) and retinoblastoma cell lines are available (controlled-access) at the European Genomics Archive. Gene expression data of primary retinoblastoma is available under GSE59983. The GSE59983 records represent the primary tissue gene expression data and the CN data will be deposited into a controlled-access database, probably EGA.

2016-03-31 | E-GEOD-77094 | biostudies-arrayexpress

Copy number profiling of 556 high-risk neuroblastoma patients using aCGH or SNP arrays

Project description:Purpose: Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk neuroblastoma, we aimed to design a prognostic classification method based on copy number aberrations. Methods: In an international collaboration, normalized high-resolution DNA copy number data (arrayCGH and SNP arrays) from 556 high-risk neuroblastomas obtained at diagnosis were collected from nine collaborative groups and segmented using the same method. We applied logistic and Cox proportional hazard regression to identify genomic aberrations associated with poor outcome. Results: In this study, we identified two types of copy number aberrations that are associated with extremely poor outcome. (i) Distal 6q losses were detected in 5.9% of patients and were associated with a ten-year survival probability of only 3.4%. (ii) Amplifications of regions not encompassing the MYCN locus were detected in 18% of patients and were associated with a ten-year survival probability of only 5.8%. Conclusion: Using a unique large copy number dataset of high-risk neuroblastoma cases, we identified a small subset of high-risk neuroblastoma patients with extremely low survival probability that might be eligible for inclusion in clinical trials of new therapeutics. The amplicons may also nominate alternative treatments that target the amplified genes.

2018-03-13 | GSE103123 | GEO

Copy number data from five primary human glioblastomas (frozen surgical resection)

Project description:DNA hypomethylation could lead to activation of alternate promoters in GBM. We profiled DNA methylation and H3K4me3 genome-wide, and also performed expression and copy number analysis on the same samples In this dataset, we include all array CGH copy number data obtained for five GBMs. We used estimated copy number to normalize sequencing-based methylation data.

2013-08-13 | GSE49808 | GEO

CBS Segmented CNA (validation set) - samples

Project description:Segmented (CBS) copy number aberrations (CNA); validation set

| EGAD00010000215 | EGA

CBS Segmented CNV (validation set) - samples

Project description:Segmented (CBS) copy number variants (CNV); validation set

| EGAD00010000216 | EGA

HMM Segmented CNA (discovery set) - samples

Project description:Segmented (HMM) copy number aberrations (CNA); discovery set

| EGAD00010000217 | EGA

CBS Segmented CNV (discovery set) - samples

Project description:Segmented (CBS) copy number variants (CNV); discovery set

| EGAD00010000214 | EGA

CBS Segmented CNA (discovery set) - samples

Project description:Segmented (CBS) copy number aberrations (CNA); discovery set

| EGAD00010000213 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data